Article
Senescent CD4+CD28null cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of-concept pilot study.
Clinical rheumatology - 1 Aug 2023
Amezcua-Guerra Luis M, Espinosa-Bautista Fernanda, Hopf-Estandía Karen, Valdivieso-Ruiz Melisa, Coronel Dania, Robledo Sandra, Ramos-Rosillo Varna, Del Rocío Martínez-Alvarado María, Patlán Mariana, Páez Araceli, Silveira Luis H, Tavera-Alonso Claudia, Massó Felipe, Soto-Fajardo Carina, Pineda Carlos
Abstract excerpt
To characterize CD4+CD28null cells in chronic hyperuricemia and investigate whether allopurinol could restore CD28 expression and the balance of T helper phenotypes. Asymptomatic individuals with chronic hyperuricemia and ultrasonographic findings evocative of urate deposition in the joints. Age- and gender-matched normouricemic individuals were also studied. Oral allopurinol at 150 mg/day for 4 weeks, followed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.